Novavax
NASDAQ:
NVAX-USD
$3.89
0.00%
Our top picks for where to buy Novavax stock
Commission-free stock trading
- No-cost financial planning and automated investing
- $0 commission on stocks, ETFs and options
- Get up to $1,000 in stock when you fund a new account within 30 days
$200 in US stocks
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Get $100-$5,000 when you open an account with $5,000 to $1,000,000+
Easy access to diverse assets
- Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
- Earn 5.1% APY on your cash
- Earn a $0.18 rebate on options, with no commissions and no per-contract fees
How to buy Novavax stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NVAX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Novavax stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 7 of 7
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AS SEEN ON:
Novavax is a biotechnology business based in the US. Novavax shares (NVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Novavax employs 1,543 staff and has a trailing 12-month revenue of around $983.7 million.
Novavax stock price (NASDAQ: NVAX)
Use our graph to track the performance of NVAX stocks over time.Novavax shares at a glance
Information last updated 2024-04-17.
| Latest market close | $3.89 |
|---|---|
| 52-week range | $3.53 - $11.36 |
| 50-day moving average | $4.67 |
| 200-day moving average | $6.16 |
| Wall St. target price | $15.40 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-5.41 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Novavax stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Novavax price performance over time
Historical closes compared with the close of $3.89 from 2024-04-17
| 1 week (2024-04-11) | -9.53% |
|---|---|
| 1 month (2024-03-18) | -24.32% |
| 3 months (2024-01-18) | -5.35% |
| 6 months (2023-10-18) | -39.88% |
| 1 year (2023-04-18) | -58.17% |
|---|---|
| 2 years (2022-04-18) | -92.95% |
| 3 years (2021-04-16) | 227.35 |
| 5 years (2019-04-18) | 10.432 |
Novavax financials
| Revenue TTM | $983.7 million |
|---|---|
| Gross profit TTM | $-156,045,000 |
| Return on assets TTM | -17.02% |
| Return on equity TTM | -898.2% |
| Profit margin | -55.41% |
| Book value | $-5.14 |
| Market Capitalization | $578 million |
TTM: trailing 12 months
Novavax share dividends
We're not expecting Novavax to pay a dividend over the next 12 months.
Have Novavax's shares ever split?
Novavax's shares were split on a 1:20 basis on 9 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.
Novavax share price volatility
Over the last 12 months, Novavax's shares have ranged in value from as little as $3.5324 up to $11.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.602. This would suggest that Novavax's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Novavax overview
Novavax, Inc. , a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc.
Frequently asked questions
What percentage of Novavax is owned by insiders or institutions?Currently 4.994% of Novavax shares are held by insiders and 57.438% by institutions. How many people work for Novavax?
Latest data suggests 1,543 work at Novavax. When does the fiscal year end for Novavax?
Novavax's fiscal year ends in December. Where is Novavax based?
Novavax's address is: 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 What is Novavax's ISIN number?
Novavax's international securities identification number is: US6700024010 What is Novavax's CUSIP number?
Novavax's Committee on Uniform Securities Identification Procedures number is: 670002401
More guides on Finder
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
10 best brokerage account bonuses of 2024
Explore the best bonuses for opening a new brokerage account.
-
11 best trading platforms for beginners 2024
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
Methodology: How we rate robo-advisors
We analyze robo-advisors across 7 key metrics to see how they compare.
-
Public.com review 2024
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
Moomoo review 2024
Features and fees to consider before you open an account with this trading platform.
-
SoFi Invest® review 2024
SoFi is a commission-free platform with both active and automated investment accounts.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Charles Schwab review 2024
Take advantage of $0 trades and no investment minimums with this well-known broker.
-
Robinhood review 2024
A deep dive into the highlights and limitations of Robinhood.
Ask a Question